secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001193805-24-001007
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic Q2 net loss $21.4M ($0.21/shr); appoints COO/President Tardio, Board member Skerjanec
--------------------------------------------------------------------------------

- Net loss of $21.4M for Q2 2024 vs $24.0M Q2 2023; diluted EPS -$0.21 on 101.3M shares.
- Cash $79.7M as of June 30, 2024; expects runway into Q3 2025.
- Jason Tardio (ex-Novartis, Biogen) appointed COO and President effective July 12, 2024.
- Simona Skerjanec (ex-Roche Neuroscience head) joined Board of Directors July 22, 2024.
- Phase 2 CALLIPER top-line data for vidofludimus calcium in PMS expected April 2025; ENSURE Phase 3 RMS trials on track.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380524001007/0001193805-24-001007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380524001007/e663826_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-24-001007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer